Scholar Rock Holding Corporation
NASDAQ: SRRK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David L. Hallal
- Employees
- 128
- Headquarters
- Cambridge, United States
- IPO year
- 2018
- Market cap
- $5.7B
- Website
- https://scholarrock.com
Loading SRRK…
Loading profile data…Frequently asked questions about SRRK
What does Scholar Rock Holding Corporation (SRRK) do?
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded P...
Where does SRRK trade?
Scholar Rock Holding Corporation (SRRK) trades on the NASDAQ Global Select.
What sector is SRRK in?
Scholar Rock Holding Corporation (SRRK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Scholar Rock Holding Corporation?
David L. Hallal is the chief executive officer of Scholar Rock Holding Corporation (SRRK).
Where is Scholar Rock Holding Corporation headquartered?
Scholar Rock Holding Corporation is headquartered in United States.
Does SRRK pay a dividend?
Scholar Rock Holding Corporation (SRRK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SRRK go public?
Scholar Rock Holding Corporation (SRRK) completed its initial public offering in 2018.